A Pilot Study of Carboplatin and Paclitaxel plus Nivolumab Immunotherapy to Treat Newly Diagnosed Advanced Ovarian Cancer


Full Title

A Pilot Study of Nivolumab with or without Ipilimumab in Combination with Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients with High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer


One possible treatment for high-grade ovarian cancer is chemotherapy with carboplatin and paclitaxel, followed by surgery, and then followed with additional carboplatin and paclitaxel. In this study, researchers want to see if it is safe and feasible to give the immunotherapy drug nivolumab with carboplatin and paclitaxel, both before and after surgery, in women newly diagnosed with high-grade ovarian cancer.

Nivolumab is approved by the FDA to treat several types of cancer, such as melanoma and lung cancer; its use for ovarian cancer is considered investigational. Nivolumab boosts the body’s immune system by targeting a protein on white blood cells called PD-1. PD-1 normally maintains the balance of the immune system by preventing it from getting overactive and can be used by tumor cells to hide from immune cells. Nivolumab blocks PD-1, enhancing the body’s ability to find and kill cancer cells.

Carboplatin, paclitaxel, and nivolumab are all given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have newly diagnosed, previously untreated high-grade stage III or IV ovarian, primary peritoneal, or fallopian tube cancer.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for women age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Claire Friedman at 646-888-4247.